Wordt geladen...
COMBINATION THERAPY WITH GLP-1 RECEPTOR AGONIST AND SGLT2 INHIBITOR
The SGLT2 inhibitors (SGLTi) and glucagon-like-1 receptor agonists (GLP-1 RAs) effectively reduce HbA1c, but via very different mechanisms, making them an effective duet for combination therapy. Recently, drugs in both of these antidiabetic classes have been shown to reduce cardiovascular events, mo...
Bewaard in:
| Gepubliceerd in: | Diabetes Obes Metab |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5643008/ https://ncbi.nlm.nih.gov/pubmed/28432726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12982 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|